Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has…
ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding…
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer…
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an…
LAUSANNE, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class…
LOS ANGELES, Dec. 17, 2024 /PRNewswire/ -- Sports and recreational injuries send more than 3.5 million Americans to the hospital…
- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership -- Build-out of GMP Manufacturing Facility to be Completed…
Hemostemix is revolutionizing how individuals think about their own regenerative medicine treatments. With social media, the company is educating about…
Keck School of Medicine of USC membership will bolster the ranks of academic and community hospitals joining the Ryght Research…
VANCOUVER, BC, Dec. 17, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company")…